{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-25-004591","form_type":"8-K","ticker":"KPTI","cik":"0001503802","company_name":"Karyopharm Therapeutics Inc.","filed_at":"2025-01-13T23:59:59+00:00","discovered_at":"2026-05-14T18:03:03.818982+00:00","generated_at":"2026-05-28T03:09:30.168288+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Karyopharm estimates FY2024 total rev ~$145M; Phase 3 MF data in 2H 2025","bullets":["Preliminary FY2024 total revenue ~$145M, XPOVIO net product rev ~$113M; Q4 rev ~$30M, XPOVIO ~$29M.","Phase 3 SENTRY trial (selinexor+ruxolitinib in MF) enrollment completion in 1H 2025, top-line data in 2H 2025.","Appointed Lori Macomber as CFO (Jan 3, 2025) and Brendan Strong as SVP IR (Dec 9, 2024).","Cash, equivalents, and investments ~$109M as of Dec 31, 2024; expected runway into Q1 2026 (excl. note repayment)."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-25-004591","json":"https://secwatch.observer/filing/0000950170-25-004591.json","markdown":"https://secwatch.observer/filing/0000950170-25-004591.md","text":"https://secwatch.observer/filing/0000950170-25-004591.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1503802/000095017025004591/0000950170-25-004591-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1503802/000095017025004591/kpti-20250113.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-28T03:09:30.168288+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}